Cogent Biosciences Secures $400M Debt Financing Facility

The latest announcement is out from Cogent Biosciences ( (COGT) ).

On June 11, 2025, Cogent Biosciences secured a non-dilutive debt financing facility of up to $400 million with SLR Capital Partners to support its growth strategy, including the anticipated 2026 launch of bezuclastinib. The initial $50 million tranche was drawn at closing, with additional funds contingent on achieving clinical and commercial milestones. This financing enhances Cogent’s financial flexibility and supports its ongoing pivotal trials, with results expected from the SUMMIT, APEX, and PEAK trials throughout 2025.

The most recent analyst rating on (COGT) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.

Spark’s Take on COGT Stock

According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.

Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.

To see Spark’s full report on COGT stock, click here.

More about Cogent Biosciences

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its most advanced clinical program involves bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is associated with systemic mastocytosis and advanced gastrointestinal stromal tumors. The company is also developing a portfolio of novel targeted therapies for other genetically driven diseases.

Average Trading Volume: 1,462,762

Technical Sentiment Signal: Hold

Current Market Cap: $844.8M

See more insights into COGT stock on TipRanks’ Stock Analysis page.